Detalhe da pesquisa
1.
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
Clin Trials
; 21(2): 211-219, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961910
2.
Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Int J Mol Sci
; 22(1)2020 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33383666
3.
A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.
bioRxiv
; 2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36909618
4.
Engineering human skin model innervated with itch sensory neuron-like cells differentiated from induced pluripotent stem cells.
Bioeng Transl Med
; 7(1): e10247, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35111948
5.
Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.
J Invest Dermatol
; 141(4): 942-946, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33069729